Kodiak Sciences Inc. announced that final end-of-study clinical results from the Phase 1b APEX trial of KSI-101 in patients with macular edema secondary to inflammation (MESI) will be presented at the Angiogenesis 2026 annual meeting on February 7, 2026. The presentation, led by Dr. Sumit Sharma from the Cole Eye Institute, will include Week 24 data and will be available on the company's website at the start of the event. The APEX study demonstrated that KSI-101 provided meaningful anatomical and visual improvements in MESI patients, regardless of the underlying cause or location of inflammation. The findings support the ongoing PEAK and PINNACLE Phase 3 studies, which are enrolling MESI patients at 5 mg and 10 mg dose levels compared to sham.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF78321) on February 04, 2026, and is solely responsible for the information contained therein.